Status:

COMPLETED

Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Femto-Lasik Surgery

Lead Sponsor:

Grigore T. Popa University of Medicine and Pharmacy

Conditions:

Dry Eye

Meibomian Gland Dysfunction (Disorder)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study evaluates the role of perioperative low-level light therapy (LLLT) in reducing dry eye disease (DED) symptoms after femtosecond laser-assisted in situ keratomileusis (Femto-LASIK). DED is o...

Detailed Description

This multicenter, randomized, double-masked, sham-controlled clinical trial was conducted to evaluate the efficacy and safety of perioperative low-level light therapy (LLLT) in preventing dry eye dise...

Eligibility Criteria

Inclusion

  • Adults aged ≥18 years.
  • Scheduled for bilateral Femto-LASIK surgery for refractive error correction.
  • Willing and able to provide written informed consent.
  • Ability and willingness to comply with all study procedures and follow-up visits.
  • Baseline ocular surface within normal limits (no pre-existing dry eye or ocular surface disease)

Exclusion

  • Prior diagnosis of ocular surface disease (OSD) or dry eye disease (DED).
  • History of ocular surgery in either eye.
  • Presence of ocular comorbidities such as glaucoma, corneal dystrophies, or active ocular infections.
  • Current or regular use of topical ocular treatments, including lubricants, corticosteroids, cyclosporine, or other drugs for DED or OSD.
  • Use of instrumental therapies for ocular surface or tear film optimization (e.g., thermal pulsation, IPL).
  • Systemic treatments known to influence tear production (e.g., diuretics, antihistamines, antidepressants, hormone replacement therapy).
  • Autoimmune diseases affecting the eyes, including Sjögren's syndrome or rheumatoid arthritis.
  • Any intraoperative or postoperative complications that could interfere with ocular surface assessment.

Key Trial Info

Start Date :

August 10 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 30 2025

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT07181668

Start Date

August 10 2024

End Date

July 30 2025

Last Update

September 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Medicine and Pharmacy "Grigore T. Popa" Iași,

Iași, Romania